Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed for diabetes management, have demonstrated remarkable cardiovascular benefits, including reduced hospitalization for heart failure and cardiovascular death, even in patients without diabetes. The gene discussed is SLC5A2; the disease is diabetes mellitus.